Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

Climacteric

Volumn 17, Issue 2, 2014, Pages 173-182

  Goldstein, S R ^a   Bachmann, G A ^b   Koninckx, P R ^c,d   Lin, V H ^e   Portman, D J ^f   Ylikorkala, O ^g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d CATHOLIC UNIVERSITY   (Italy)

^e QuatRx Pharmaceuticals Company   (United States)

^f Columbus Center for Women's Health Research ^*  (United States)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Dyspareunia; Efficacy; Endometrial Safety; Maturation Index; Safety; Vaginal Effects

Indexed keywords

ESTRADIOL; FOLLITROPIN; GESTAGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; OSPEMIFENE; PLACEBO; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BACKACHE; CONTROLLED STUDY; CURETTAGE; CYSTITIS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIAL THICKNESS; ENDOMETRIUM BIOPSY; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MATURATION; MEDICATION COMPLIANCE; MIOSIS; MUSCLE SPASM; PATIENT COMPLIANCE; PH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA EPITHELIUM; VAGINA SMEAR; VERY ELDERLY; VULVA DISEASE; VULVAR AND VAGINAL ATROPHY; ANALOGS AND DERIVATIVES; ATROPHY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ATROPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA;

EID: 84896373301     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.834493     Document Type: Article

References (48)

1. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000; 61: 3090-6 (Pubitemid 30347020)
2. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 355-69
3. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009; 6: 2133-42
4. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004; 49: 292-303 (Pubitemid 39505183)
5. Simon JA, Komi J. Postmenopausal women's attitudes: vulvovaginal atrophy and its symptoms [abstract LB-10]. Menopause 2007; 14: 1107
6. Freedman M, Reape KZ, Giblin K. Impact of menopausal symptoms on sex lives: a survey evaluation [abstract LB-12]. Menopause 2007; 14: 1107
7. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008; 15: 661-6
8. Mac Bride M B, Rhodes D J, Shuster L T. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94
9. Gass M L, Cochrane BB, Larson J C, et al. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause 2011; 18: 1160-71
10. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009; 12: 91-105
11. Barlow D H, Samsioe G, v an Geelen J M. Astudy of European womens ' experience of the problems of urogenital ageing and its management. Maturitas 1997; 27: 239-47 (Pubitemid 27356256)
12. Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543-51
13. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275: 370-5
14. Kagan R. Therapeutic options for the treatment of vaginal atrophy. OBG Management 2010; 22: S8-13
15. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-55
16. Santen R J, Pinkerton J V, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002; 9: 179-87 (Pubitemid 34492326)
17. Kingsberg S A, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10: 1790-9
18. Nath A, Sitruk-Ware R. Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric 2009; 12: 188-205
19. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-29 (Pubitemid 36210865)
20. Ball L, Levy N, Zhao X, et al. Cell type- and estrogen receptorsubtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol Cell Endocrinol 2009; 299: 204-11
21. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87: 905-31 (Pubitemid 47084672)
22. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000; 141: 809-20 (Pubitemid 32250507)
23. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC- 1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002; 43: 207-14 (Pubitemid 35346550)
24. Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol 2005; 97: 230-40 (Pubitemid 41607573)
25. EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003; 10: 433-9
26. Bachmann G A, Komi J O. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010; 17: 480-6
27. Simon J A, Lin V H, Radovich C, Bachmann G A. One-year longterm safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2012; 20: 418-27
28. Portman D J, Bachmann G A, Simon J A. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623-30
29. Mutter G L, Ferenczy A. Anatomy and histology of the uterine corpus. In Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 5th edn. New York: Springer-Verlag, 2002: 383-420
30. Ellm é n J, Hakulinen P, Partanen A, Hayes DF. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat 2003; 82: 103-11 (Pubitemid 37476010)
31. Plouffe L Jr, Siddhanti S. The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis. Ann N Y Acad Sci 2001; 949: 251-8 (Pubitemid 34059987)
32. Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 2010; 17: 642-53
33. Taylor HS. Designing the ideal selective estrogen receptor modulator - an achievable goal? Menopause 2009; 16: 609-15
34. Delmanto A, Nahas-Neto J, Nahas EA, de Oliveira ML, Fernandes CE, Traiman P. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2008; 139: 187-92
35. Fisher B, Costantino J P, Wickerham D L, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-62 (Pubitemid 41672231)
36. Goldstein SR. Not all SERMs are created equal. Menopause 2006; 13: 325-7
37. Marttunen M B, Cacciatore B, Hietanen P, Pyrhönen S, Wahlström T, Ylikorkala O. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001; 84: 897-902 (Pubitemid 32385831)
38. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7: 156-61 (Pubitemid 30249896)
39. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006: Issue 4
40. Vagifem [package insert]. Princeton, NJ: Novo Nordisk Inc.; 2012
41. Dreisler E, Sorensen S S, Ibsen P H, Lose G. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20-74 years. Ultrasound Obstet Gynecol 2009; 33: 102-8
42. Burich R A, Mehta N R, Wurz G T, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag. Tg transgenic mouse model. Menopause 2012; 19: 96-103
43. Wurz GT, Soe LH, DeGregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 2013 Jan 15. Epub ahead of print
44. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001; 77: 271-9 (Pubitemid 32703625)
45. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging 2008; 8: 135-45 (Pubitemid 351936271)
46. McClung M R, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006; 13: 377-86
47. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37 (Pubitemid 44050394)
48. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160: 3444-50